COMPASS Pathways Plc is a biotechnology company developing evidence-based treatments for serious mental health conditions. The company's primary focus is the development of COMP360, a proprietary psilocybin formulation designed for the treatment of treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 is a pharmaceutical-grade polymorphic crystalline psilocybin optimized for stability and purity. The company is currently advancing a Phase 3 clinical program for TRD, which includes two pivotal trials, and has initiated a Phase 2b/3 clinical trial for PTSD following FDA acceptance of its Investigational New Drug application. COMPASS Pathways retains global development and commercialization rights for its investigational treatment. The company plans to launch in the United States as its first market, with commercial planning activities underway to ensure readiness for potential FDA approval. It collaborates with various healthcare delivery systems in the U.S. to research models for the scalable delivery of its treatment. The company received Breakthrough Therapy designation from the FDA for COMP360 in TRD in 2018.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage compasspathways.com
Sector Healthcare IR page ir.compasspathways.com/overview/default.aspx
Tags
mental health, treatment-resistant depression, post-traumatic stress disorder, psilocybin, clinical trials, neuropsychiatry, psychedelic medicine, COMP360, COMP005, COMP006, COMP202
Press page —

Metrics

Valuation  
Market cap $ 1.763B
Market cap (USD) $ 1.763B
P/E -3.57
PEG —
P/BV 12.41
P/S —
P/OCF -9.97
P/FCF -11.21
Dividend yield —
Turnover / mcap —
Returns  
ROE 544.7%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 35.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 65
Quality score -45.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Assets 210.349M 213.666M 275.987M 197.294M 300.898M 203.456M 32.389M
Net profit -287.862M -155.122M -118.464M -91.505M -71.742M -60.334M -19.612M
Free cash flow -157.24M -119.186M -97.442M -106.047M -68.079M -41.511M -17.978M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 6.9 3.78 8.75 8.03 22.1 47.64 38
Price performance 12m 0.83 -0.57 0.09 -0.64 -0.54 0.25 —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — — — — 0.00 5.51M 17.5M
Borrowings, non-current (USD) — — — — — 28.8M 24.7M 14.1M
Lease liabilities (USD) — — 1M 3.61M 1.93M 4.29M 2.03M 3.4M
Cash and deposits (USD) 22.9M 25M 190M 273M 143M 220M 165M 150M
Right-of-use assets (USD) — — 1M 3.7M 2.01M 4.31M 2.01M 3.42M
Net debt (borrowings + leases - cash) (USD) — — — — — -187M -133M -115M
Cash flow detail
Operating cash flow (USD) — -17.8M -41.4M -67.7M -105M -97.4M -119M -157M
Purchases of property, plant and equipment (USD) — -165,000 -131,000 -334,000 -596,000 -66,000 0.00 —
Change in payables (cash effect) (USD) — 580,000 1.3M -163,000 2.5M 864,000 6.59M 2.03M
Interest paid (cash effect) (USD) — — — 0.00 0.00 -1.25M -3.07M -3.05M
Income taxes paid (cash effect) (USD) — — — — — -2.44M -1.12M -755,000
Share-based compensation (USD) — 3.25M 18M 8.64M 13.1M 17.3M 19.5M 13.6M
Free cash flow (OCF - PPE - intangibles) (USD) — -18M -41.5M -68.1M -106M -97.4M -119M —
Income detail
Research and development expense (USD) — 12.6M 23.4M 44M 65.1M 87.5M 119M 118M
↳ 5y CAGR +56.8% +38.4%
Total comprehensive income (USD) — -19.3M -45.7M -77.5M -117M -119M -154M -286M
Comprehensive income to owners (USD) — -19.3M -45.7M -77.5M -117M -119M -154M -286M
Reported Mar 9, 2021 Mar 9, 2021 Feb 24, 2022 Feb 29, 2024 Feb 29, 2024 Feb 27, 2025 Feb 27, 2025 Mar 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Launch readiness on track for expected launch in H12027, subject to FDA approval

•Data from two positive Phase 3 trials reinforce COMP360's unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year

•The Phase 3 data supports the belief that COMP360 has the potential to establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year

•COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S.

October 28, 2026

  • Download (opens in new window)

  • Disease education booth underscores continued commitment to advancing understanding of treatment-resistant depression (TRD) among U.S. healthcare professionals (HCPs)

  • Encore poster presentations highlight key safety, efficacy and patient demographics data from the COMP360 psilocybin clinical program in TRD

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participation at the 2026 Neuroscience Education Institute (NEI) Fall Congress, taking place in Colorado Springs, CO, from November 5-8. The Company will feature its Change the Tune in TRD educational campaign for U.S. HCPs focused on TRD, as well as encore presentations from its COMP360 psilocybin clinical development program.

Change the Tune in TRD: Advancing HCP Education

Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated with TRD, as well as insights into the impact on patients in navigating treatment. A three-panel discussion will be presented at the Breakfast Industry Session on Sunday, November 8th from 7:00-8:00am in the International Center. The featured panelists include:

  • Saundra Jain MA, PsyD, LPC, Psychotherapist, Adjunct Clinical Affiliate, University of Texas at Austin School of Nursing; Private Practice, Austin, Texas

  • Bryan B. Shapiro MD, MPH, Board-Certified Psychiatrist, Assistant Clinical Professor of Psychiatry, UC Irvine Medical Center

  • Sandhya Prashad, MD, Interventional Psychiatrist, Medical Director at Houston Center for Advanced Psychiatric Treatment

U.S. HCPs can learn more at ChangeTheTuneInTRD.com .

Encore COMP360 Presentations

  • Efficacy and Safety of COMP360 Psilocybin for ​Treatment-Resistant Depression (TRD) in Two Phase 3, ​Double-blind, Randomized, Controlled Studies
  • Demographic and Clinical Characteristics of Participants Receiving COMP360 Psilocybin Treatment for Treatment-Resistant Depression Across Two Pivotal Phase 3 Trials

About treatment resistant depression (TRD)

Depression , one of the most common mental health disorders, significantly impacts relationships, work performance, overall quality of life, and is associated with an increased risk of suicide. Major depressive disorder (MDD) has been ranked as the third cause of the burden of disease worldwide in 2008 by the World Health Organization (WHO), which has projected that this disease will rank first by 2030.

It is estimated that approximately 4 million patients in the U.S. with MDD live with TRD1. TRD is broadly defined as an inadequate response to two or more appropriate courses of approved antidepressant medications. TRD has a significantly greater impact on individuals compared to MDD, including residual symptoms, poorer quality of life, increased comorbidities, higher mortality, and an increased risk of suicide.

About Compass Pathways

We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. We are leading the world’s largest classic psychedelic clinical program in TRD, and building upon that robust foundation, we are executing a late-stage trial evaluating COMP360 for PTSD, another condition with high unmet need. Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing.

Compass is headquartered in London, UK, with a U.S. office in New Jersey.

We are driven by our purpose of unlocking pathways to be – opening futures filled with possibility. Together, we are on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery, because every journey needs a Compass.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, statements regarding our business strategy and goals; our expectations regarding the safety or efficacy of our investigational COMP360 psilocybin treatment, including as a treatment for treatment of TRD; our plans and expectations regarding our clinical trials; any implication that preliminary results will be predictive of full safety and efficacy data from our phase 3 program; the potential for our current or any future clinical trials to support regulatory filings and approvals for COMP360 psilocybin treatment on an accelerated basis or at all; our ability to obtain regulatory approval and adequate coverage and reimbursement; our ability to transition from a clinical-stage to a commercial-stage organization and effectively launch a commercial product, if regulatory approval is obtained; our expectations regarding our commercial readiness, if regulatory approval is obtained; and our expectations regarding the benefits of our investigational COMP360 psilocybin treatment. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Compass’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; the full results and safety data from our Phase 3 clinical trials in TRD may not be consistent with the preliminary results; our need for substantial additional funding to achieve our business goals and if we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our clinical trials; our efforts to obtain FDA approval, or approval from regulatory authorities in other jurisdictions, for our investigational COMP360 psilocybin treatment on an accelerated basis, or at all, may be unsuccessful; our efforts to commercialize and obtain coverage and reimbursement for our investigational COMP360 psilocybin treatment, if approved, may be unsuccessful; and those risks and uncertainties described under the heading “Risk Factors” in Compass’s most recent annual report on Form 10-K or quarterly report on Form 10-Q and in other reports we have filed with the U.S. Securities and Exchange Commission (“SEC”), which are available on the SEC’s website at www.sec.gov . Except as required by law, Compass disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Compass’s current expectations and speak only as of the date hereof.

1. Wing V, et al. Poster S97 Contemporary Estimate of the National Prevalence of Treatment-Resistant Depression in the United States. Presented at ADAA 2026.

Enquiries
Media: Dana Sultan-Rothman, [email protected]

Investors: Stephen Schultz, [email protected] , +1 401 290 7324

Source: Compass Pathfinder Limited

View All News

October 27, 2026

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the third quarter ended September 30, 2026, and provide an update on recent developments, on November 3, 2026.

Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 3, 2026. A live webcast of the call will be available at the following link: https://lifescievents.com/event/csy40je/ . The webcast will be archived for 30 days.

About Compass Pathways

We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. We are leading the world’s largest classic psychedelic clinical program in TRD, and building upon that robust foundation, we are executing a late-stage trial evaluating COMP360 for PTSD, another condition with high unmet need. Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing.

Compass is headquartered in London, UK, with a U.S. office in New Jersey.

We are driven by our purpose of unlocking pathways to be – opening futures filled with possibility. Together, we are on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery, because every journey needs a Compass.

Enquiries
Media: Dana Sultan-Rothman, [email protected]

Investors: Stephen Schultz, [email protected] , +1 401 290 7324

Source: Compass Pathfinder Limited

View All News

Prompts

COMPASS Pathways Plc (ticker CMPS), listed in United States.

Company History

Date Change Detail
Jul 31, 2020 Renamed Compass Rx Ltd. → COMPASS PATHWAYS PLC

ETFs Holding COMPASS Pathways Plc

ETF Weight in ETF Shares Market value As of
PSIL 10.35% 494,395 $ 3.945M Nov 17, 2026
ARKG 2.59% 5,902,847 $ 47.105M Nov 18, 2026
AADR 1.30% 53,103 $ 423.762K Nov 17, 2026
SURI 1.06% 90,381 $ 721.24K Nov 17, 2026
APIE 0.02% 18,739 $ 253.164K Aug 31, 2026